middle.news
How Argent BioPharma’s AusCann Deal Could Transform CannEpil’s Future
8:04pm on Friday 27th of February, 2026 AEDT
•
Healthcare
Read Story
How Argent BioPharma’s AusCann Deal Could Transform CannEpil’s Future
8:04pm on Friday 27th of February, 2026 AEDT
Key Points
Half-year net loss narrowed to A$2.9 million from A$12.2 million
Binding agreement signed to acquire AusCann assets, advancing CannEpil
Positive US in vivo study supports ArtemiC™ efficacy in viral inflammation
EU-GMP cannabinoid API supply commenced at leading EU hospital
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ARGENT BIOPHARMA (ASX:RGT)
OPEN ARTICLE